Is Pasithea Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: KTTA) stock is to Strong Buy KTTA stock.
Out of 1 analyst, 1 (100%) are recommending KTTA as a Strong Buy, 0 (0%) are recommending KTTA as a Buy, 0 (0%) are recommending KTTA as a Hold, 0 (0%) are recommending KTTA as a Sell, and 0 (0%) are recommending KTTA as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year KTTA price target, the average KTTA price target is $2.00, with the highest KTTA stock price forecast at $2.00 and the lowest KTTA stock price forecast at $2.00.
The Wall Street analyst predicted that Pasithea Therapeutics's share price could reach $2.00 by Jul 10, 2024. The average Pasithea Therapeutics stock price prediction forecasts a potential upside of 502.41% from the current KTTA share price of $0.33.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.